Welcome to our dedicated page for Applied Genetic news (Ticker: AGTC), a resource for investors and traders seeking the latest updates and insights on Applied Genetic stock.
The AGTC (Applied Genetic Technologies Corporation) news archive on Stock Titan covers the company’s history as a clinical-stage biotechnology developer of adeno-associated virus (AAV)-based gene therapies for rare and debilitating ophthalmic, otologic and central nervous system (CNS) diseases. News releases repeatedly describe AGTC’s focus on inherited retinal diseases, with its most advanced clinical programs in X-linked retinitis pigmentosa (XLRP) and achromatopsia due to CNGB3 variants (ACHM CNGB3).
Readers will find detailed coverage of the strategic transaction in which a portfolio company of Syncona Limited agreed to acquire AGTC through a tender offer and subsequent merger. Multiple releases from October through December 2022 outline the tender offer terms, the board’s unanimous recommendation, reminders to shareholders about tender deadlines, and the final confirmation that the acquisition closed and AGTC became an indirect, wholly owned subsidiary of Syncona Limited, with its common stock delisted from the Nasdaq Global Stock Market.
The archive also includes earlier corporate updates, such as announcements about AGTC’s participation in investor conferences and reiterations of its development strategy in AAV-based gene therapy, inherited retinal disease programs, and preclinical work in optogenetics, otology and CNS disorders. In addition, later news from Beacon Therapeutics references laru-zova (laruparetigene zovaparvovec), described in a presentation title as “AGTC-501,” providing continuity for those tracking the historical XLRP program originally developed at AGTC.
Investors, researchers and industry observers can use this news page to review AGTC’s public communications, understand the rationale and structure of the Syncona acquisition, and follow how AGTC’s legacy XLRP asset is referenced in subsequent clinical trial updates from Beacon Therapeutics.
Applied Genetic Technologies Corporation (Nasdaq: AGTC) reported positive interim results from its Phase 2 Skyline trial of AGTC-501, a gene therapy for X-linked retinitis pigmentosa (XLRP). 62.5% of patients in dose group B showed improvements in visual sensitivity, exceeding the FDA's requirements. The therapy was well-tolerated, with no serious safety concerns reported. A conference call is scheduled for May 17 to discuss the findings further. AGTC aims to leverage these results in upcoming regulatory submissions.
Summary not available.
Applied Genetic Technologies Corporation (AGTC) announced positive findings from the ongoing Phase 1/2 trial of AGTC-501 for treating X-linked retinitis pigmentosa (XLRP). Data presented at the ARVO 2022 meeting show sustained safety and efficacy over 18 months, with two-thirds of patients recovering foveal ellipsoid zone (EZ) and nearly half reporting improved macular sensitivity. AGTC-501 demonstrated good tolerability, with mostly mild adverse events. The company is optimistic about AGTC-501's potential and plans to share more results from ongoing trials later in 2022.
Applied Genetic Technologies Corporation (Nasdaq: AGTC) revealed promising preclinical data at the 25th Annual Meeting of the ASGCT, focusing on gene therapies for inherited retinal diseases and expanding to neurodegenerative diseases like frontotemporal dementia (FTD). The data showed sustainable expression of progranulin via AAV vectors in non-human primates, potentially addressing FTD caused by GRN mutations. The company's approaches also include a hybrid dual AAV strategy for Stargardt disease, showcasing advancements in AAV technology and paving the way for future clinical developments.
Applied Genetic Technologies Corporation (Nasdaq: AGTC) announced that Sue Washer, President & CEO, will present at the Alliance for Regenerative Medicine Cell & Gene Meeting in Barcelona on April 21 at 9:30 PM CEST. AGTC focuses on AAV-based gene therapies for rare diseases, particularly inherited retinal diseases. The company is advancing clinical trials for X-linked retinitis pigmentosa and achromatopsia, alongside preclinical programs in optogenetics and CNS disorders. For more details, visit meetingonthemed.com.
Applied Genetic Technologies Corporation (Nasdaq: AGTC) announced multiple presentations at the ARVO 2022 annual meeting concerning ongoing clinical trials in X-linked retinitis pigmentosa (XLRP) and achromatopsia (ACHM). Key presentations include interim safety results and findings on visual photosensitivity from Phase 1/2 trials. With a focus on gene therapy for rare inherited retinal diseases, AGTC aims to validate its technology platform. Results from these studies may support future regulatory filings, emphasizing the potential impact of AGTC’s therapies on patient care.
Applied Genetic Technologies Corporation (AGTC) announced a public offering of 7,500,000 shares of its common stock, aiming for approximately $9.8 million in gross proceeds. The offering is slated to close on or around March 24, 2022, subject to customary conditions. AGTC intends to use the proceeds to support its ongoing clinical trials in the X-linked retinitis pigmentosa (XLRP) and Achromatopsia (ACHM) programs, as well as for general corporate purposes. Cantor Fitzgerald & Co. is the sole book-running manager for the offering.
Applied Genetic Technologies Corporation (AGTC) has launched an underwritten public offering of its common stock, with all shares being sold by the company. The offering includes a 30-day option for the underwriter to purchase an additional 15% of shares. Proceeds will support ongoing clinical trials in its X-linked retinitis pigmentosa (XLRP) and Achromatopsia (ACHM) programs and other corporate purposes. Cantor Fitzgerald & Co. is the sole book-running manager for the offering, which is subject to market conditions and cannot be guaranteed to complete.
Applied Genetic Technologies Corporation (Nasdaq: AGTC) announced participation in several upcoming virtual investor conferences. Jon Lieber, CFO, will present at the 34th Annual ROTH Conference on March 13-15, 2022. Sue Washer, President and CEO, will be on a panel at the Cantor Fitzgerald Virtual Rare Orphan Disease Summit on March 29, 2022, discussing gene therapy for rare diseases. Additionally, a fireside chat with Ms. Washer will be held at the H.C. Wainwright Gene Therapy and Gene Editing Conference on March 30, 2022. Replays of the events will be available on the Company's website.
Applied Genetic Technologies Corporation (Nasdaq: AGTC) announced its financial results for the quarter ending December 31, 2021, reporting a net loss of $19.1 million. The company is preparing to release interim results from the SKYLINE trial in Q2 2022 and expects to provide further updates on its X-linked retinitis pigmentosa (XLRP) and achromatopsia programs. AGTC has enrolled 14 patients in the SKYLINE trial, exceeding its target. The company is also progressing on its new manufacturing facility, aiming for initial operations in Q4 2022.